News & Events

Learn about what's new with CMC Biologics

Global Bioproduction Summit 2018, Feb 5-6, San Diego


BIOP_Email Banner_200x100.jpgJoin us at the 17th Annual Global Bioproduction Summit in sunny San Diego!  We'll be at Booth #6, February 5-6, so please make sure to stop by.

The Bioproduction Summit is a great source for highly technical content focusing on the key challenge areas of biopharmaceutical development. You'll find solutions to the most critical challenges in R&D, upstream, downstream and manufacturing excellence.

Key topics on the agenda include purification, quality, tech transfer, validation, CMC development and single-use technologies.

AGC Biologics Technical Seminars, Jan 23 & 25, 2018, South Korea and Taiwan



AGC Biologics will be holding two technical seminars in January, with the theme Development of Biologics and Speed to IND, and a focus on early-phase development and manufacturing.

January 23: Seoul, South Korea, Hotel Intercontinental Soul Coex
January 25: Taipei City, Taiwan, Humble House Taipei

AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics


BOTHELL, Wash., BERKLEY, Calif., COPENHAGEN, DK, HEIDELBERG, DE, CHIBA & YOKOHAMA, JAPAN ─ January 8, 2018 ─ AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, announced today that effective January 8, 2018, the company will be integrated and newly branded as 
AGC Biologics.

CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics


BOTHELL, Wash., BERKELEY, Calif., and SOUTH SAN FRANCISCO, Calif., USA -- December 12, 2017 -- CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Harpoon Therapeutics, an immuno-oncology company using its proprietary TriTAC™ technology platform to discover and develop novel biologics for the treatment of cancer, announced today they have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC™ molecules for the treatment of various human cancers.

Biotech Showcase 2018, Jan 8-10, 2018, San Francisco, CA


Join us at Biotech Showcase 2018, at the Hilton San Francisco Union Square.

J.P. Morgan 36th Annual Healthcare Conference, Jan 8-11 2018


We'll see you at J.P. Morgan 2018 in San Francisco, CA!

The J.P. Morgan Healthcare Conference hosts one of the largest and most informative healthcare investment symposiums in the industry.

In 2018 there will likely be 400 companies, both public and private, delivering presentations to more than 8,000 attendees.

CMC Biologics and Aptevo Therapeutics Enter into Commercial Manufacturing Agreement for IXINITY®


Bothell, WA and Seattle, WA – August 22, 2017 – CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and Aptevo Therapeutics (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that they have entered into an agreement for the continued commercial manufacture of Aptevo’s factor IX therapeutic, IXINITY® Coagulation Factor IX (Recombinant). 

CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience


Development of Trellis’ monoclonal antibody (mAb) using CMC Biologics’ proprietary CHEF1® Expression Platform and Multi-column Continuous Chromatography (MCC) Technology



BIO International 2017, June 19 - 22, San Diego, CA, Booth #1425


June 19 - 22, 2017 
BIO International Convention, San Diego, CA

CMC Biologics is pleased to be exhibiting at the 2017 BIO International Convention, to be held in sunny San Diego, California. Please visit us in the Bio Process Zone at booth #1425.

And to promote the recent establishment of our Seattle office as Headquarters for AGC's Life Science division, we invite convention attendees to our booth for a fun trivia contest!

Altor BioScience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor’s IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trials


BOTHELL, Washington and MIRAMAR, Florida, U.S.A., April 13, 2017—CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Altor BioScience Corporation (“Altor”), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases, today announced that they have entered into a manufacturing agreement for the cGMP manufacturing of Altor’s ALT-803 molecule for use in Phase 3 clinical trials.

View or Download as a PDF  

Follow Us
Join us on LinkedIn Follow us on Twitter